Тромбоцитопенические синдромы во время беременности

1. Cines D.B., Levine L.D. Thrombocytopenia in pregnancy. Blood. 2017; 130(21): 2271-7. https://doi.org/10.1182/blood-2017-05-781971
2. Fogerty A.E. Thrombocytopenia in pregnancy: mechanisms and management. Transfusion medicine reviews. 2018; 32(4): 225-9. doi:10.1016/ j.tmrv.2018.08.004.
3. Chaturvedi S., McCrae K.R. Thrombocytopenia in pregnancy. Platelets in Thrombotic and Non-Thrombotic Disorders: Pathophysiology, Pharmacology and Therapeutics: an Update. Springer International Publishing. 2017; 813-823.https://doi.org/10.1007/978-3-319-47462-5_54
4. Parnas M., et al. Moderate to severe thrombocytopenia during pregnancy. Eur J Obstet Gynecol Reprod Biol. 2006; 128(1-2):163-8. DOI:10,1016/ j.ejogrb.2005.12.031
5. Valera M.C., Parant O., et.al. Physiologic and pathologic changes of platelets in pregnancy. Platelets. 2010; 21(8): 587-95. DOI:10,3109/ 09537104.2010.509828
6. Palta A., Dhiman P. Thrombocytopenia in pregnancy. Journal of Obstetrics and gynecology. 2016; 36(2): 146-52. https://doi.org/10.3109/01443615.2015.1041893
7. Webert K.E., Mittal R., Sigouin C., Heddle N.M., Kelton J.G. A retrospective 11-year analysis of obstetric patients with idiopathic thrombocytopenic purpura. Blood. 2003; 102(13): 4306-11. DOI:10,1182 / Blood-2002-10-3317
8. Fujimura K., Harada Y., Fujimoto T., et al. Nationwide study of idiopathic thrombocytopenic purpura in pregnant women and the clinical influence on neonates. Int J Hematol. 2002; 75(4): 426-33. PMID:12041677
9. Loustau V., Debouverie O., Canoui-Poitrine F., et al. Effect of pregnancy on the course of immune thrombocytopenia: a retrospective study of 118 pregnancies in 82 women. Br J Haematol. 2014; 166(6): 929-35. DOI: 10,1111 / bjh.12976
10. Lefkou E., Hunt B.J. Bleeding disorders in pregnancy. Obstetrics, Gynaecology and Reproductive medicine. 2018; 28(7):189-195. DOI: 10.1016/j.ogrm.2018.06.002
11. Karim R., Sacher R.A. Thrombocytopenia in pregnancy. Curr Hematol Rep. 2004; 3(2):128-33. PMID: 14965489
12. Neunert C., Lim W., Crowther M., et al. The American society of hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011; 117(16): 4190-207. doi:10.1182 / blood-2010-08-302984
13. Provan D., Stasi R, Newland A.C., et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115(2):168-86. doi: 10.1182 / blood-2009-06-225565.
14. British Committee for standards in Haematology General Haematology Task Force. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol. 2011; 120(4): 574-96.
15. Mizutani H., Furubayashi T., Imai Y., Kashiwagi H., Honda S., Take H., Kurata Y., Yonezawa T., Tarui S., Ikehara S. Mechanisms of corticosteroid action in immune thrombocytopenic purpura (ITP): experimental studies using ITP-prone mice, (NZW x BXSB) F1. Blood. 1992; 79(4): 942-7.PMID: 1737103
16. Jin F., Balthasar J.P. Mechanisms of intravenous immunoglobulin action in immune thrombocytopenic purpura. Hum Immunol. 2005; 66(4): 403-10. https://dx.doi.org/10.1016/j.humimm.2005.01.029
17. Sun D. Shehata N., Ye XY, Gregorovich S., De France B., Arnold D.M., et al. Corticosteroids compared with intravenous immunoglobulin for the treatment of immune thrombocytopenia in pregnancy. Blood. 2016; 128(10): 1329-35. doi: 10.1182/blood-2016-04-710285
18. Hviid A and Molgaard-Nielsen D. Corticosteroid use during pregnancy and risk of orofacial clefs. CM AJ. 2011; 183(7): 796-804. DOI: https://doi.org/10.1503/cmaj.101063
19. Park-Wyllie, Mazzotta P, Pastuszak A., et al. Birth defects after maternal exposure to corticosteroids: progressive cohort study and meta-analysis of epidemiological studies. Teratology. 2000; 62(6): 385-92. PMID: 11091360
20. Wang X., Xu Y., Luo W., Feng H., Luo Y., Wang Y. et al. Thrombocytopenia in pregnancy with different diagnoses. Differential clinical features, treatments, outcomes. Medicine. 2017; 96(29): е7561. http://dx.doi.org/10.1097/MD.0000000000007561
21. Abalos E., Cuesta C., Grosso A.L., et al. Global and regional estimates of preeclampsia and eclampsia : a systematic review. Eur J Obstet Gynecol Reprod Biol. 2013;170(1):1-7. doi: 10.1016/j.ejogrb.2013.05.005
22. Ananth C.V., Keyes K.M., Wabner R.J. Pre-eclampsia rates in the United States, 1980-2010: age-period-cohort analysis. BMJ. 2013; 347:f6564. doi: 10.1136/bmj.f6564
23. Daley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol. 2009; 33(3):130-7. doi: 10.1053/j.semperi.2009.02.010
24. ACOG. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists task force on hypertension in pregnancy. Obstet Gynecol. 2013; 122(5):1122-31. doi: 10.1097/01.AOG.0000437382.03963.88
25. Bartsch E., Medcalf K.E., Park A.L., Ray J.G. Clinical risk factors for preeclampsia determined in early pregnancy: systematic review and meta-analysis of large cohort studies. BMJ. 2016; 353: i1753. doi: 10.1136/bmj.i1753
26. McCrae K.R. Thrombocytopenia in pregnancy: differential diagnosis, pathogenesis, and management. Blood Rev. 2003; 17(1): 7-14. PMID: 12490206
27. Макацария А.Д., Акиньшина С.В., Бицадзе В.О. Преэклампсия и HELLP-синдром как проявление тромботической микроангиопатии. Акушерство и гинекология. 2014; 4: 4-10.
28. Rinehart B.K., Terrone D.A., May W.L., Magann E.F., Isler C.M., Martin J.N. Jr. Change in platelet count predicts eventual maternal outcome with syndrome of hemolysis, elevated liver enzymes and low platelet count. J Matern Fetal Med. 2001;10(1): 28-34. PMID: 11332416
29. Kirkpatrick C.A. The HELLP-syndrome. Acta Clin Belg. 2010; 65(2): 91-7. DOI: 10.1179/acb.2010.020
30. Mao M., Chen C. Corticosteroid therapy for management of hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome: a meta-analysis. Med Sci Monit. 2015; 21: 3777-3783. DOI: 10.12659/msm.895220
31. Rose C.H., Thigpen B.D., Bofill J.A., Cushman J., May W.L., Martin J.N. Jr. Obstetric implications of antepartum corticosteroid therapy for HELLP syndrome. Obstet Gynecol. 2004; 104(5 Pt 1): 1011-4. DOI: 10.1097/01.AOG.0000143262.85124.e8
32. Barrilleaux P.S., Martin Jr J.N., Klauser C.K., et al. Postpartum intravenosus dexamethasone for severely preeclamptic patients without HELLP-syndrome: a randomized trial. Obstet Gynecol. 2005; 105(4): 843-8. DOI: 10.1097/01.AOG.0000154887.57440.d1
33. Katz L., de Amorim M.M., Figueiroa J.N., et al. Postpartum dexamethasone for women with (HELLP) syndrome: a double-blind, placebo-controlled, randomized clinical trial. Am J Obstet Gynecol. 2008; 198(3): 283.e1-8. DOI: 10.1016/j.ajog.2005.07.037
34. Kentouche K., Voigt A., Schleussner E., Schneppenheim R., Budde U., Beck J.F., Stefańska-Windyga E., Windyga J. Pregnancy in Upshaw-Schulman syndrome. Hamostaseologie. 2013; 33(2): 144-8. DOI: 10.5482/HAMO-13-04-0025
35. Sadler J.E. Pathophysiology of thrombotic thrombocytopenic purpura. Blood. 2017; 130(10): 1181-8. DOI: 10.1182/blood-2017-04-636431
36. Tsai H.M. Pathophysiology of thrombotic thrombocytopenic purpura. Int J Hematol. 2010; 91(1): 1-19. doi:10.1007/s12185-009-0476-1
37. McMinn J.R., George J.N. Evaluation of women with clinically suspected thrombotic thrombocytopenic purpura-hemolytic uremic syndrome during pregnancy. J Clin Apher. 2001;16(4):202-9.PMID: 11835417
38. Martin J.N. Jr, Bailey A.P., Rehberg J.F., Owens M.T., Keiser S.D., May W.L. Thrombotic thrombocytopenic purpura in 166 pregnancies: 1955-2006. Am J Obstet Gynecol. 2008 Aug; 199(2): 98-104. DOI:10.1016/j.ajog.2008.03.011
39. George J.N., Nester C.M., Mclntosh J.J. Syndromes of thrombotic microangiopathy associated with pregnancy. Hematology Am Soc Hematol Educ Program. 2015; 2015: 644-8. DOI: 10.1182/asheducation-2015.1.644
40. Vesely S.K., Li X., McMinn J.R., Terrell D.R., George JN. Pregnancy outcomes after recovery from thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Transfusion. 2004; 44(8):1149-58. DOI: 10.1111/j.1537-2995.2004.03422.x
41. Moatti-Cohen M., Garrec C., Wolf M., et al. French Reference Center for Thrombotic Microangiopathies. Unexpected frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura. Blood. 2012; 119(24): 5888-97. doi: 10.1182/blood-2012-02-408914
42. Scully M., Thomas M., Underwood M., et al. Collaborators of the UK TTP registry. Thrombotic thrombocytopenic purpura and pregnancy: presentation, management, and subsequent pregnancy outcomes. Blood. 2014; 124(2): 211-9. doi: 10.1182/blood-2014-02-553131.
43. Scully M. Thrombotic thrombocytopenic purpura and atypical hemolytic uremic syndrome microangiopathy in pregnancy. Semin Thromb Hemost. 2016; 42(7): 774-779. DOI: 10.1055/s-0036-1587683
44. Saad A., Roman J., Wyble A., Pacheco L. D. Pregnancy-associated atypical hemolytic-uremic syndrome. AJP Rep. 2016; 6(1): e125-e128. doi: 10.1055/s-0036-1579539.
45. Laurence J., et al. Atypical hemolytic uremic syndrome (aHUS): essential aspects of an accurate diagnosis. Clin Adv Hematol Oncol. 2016.; 14 Suppl 11(11): 2-15. PMID: 27930620
46. Caprioli J., Noris M., Brioschi S., et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood. 2006. 15; 108(4): 1267-79. DOI: 10.1182/blood-2005-10-007252
47. Fakhouri F., Roumenina L., Provot F., et al. Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J Am Soc Nephrol. 2010; 21(5): 859-67. doi: 10.1681/ASN.2009070706
48. Andries G., Karass M., Linder K., et al. Atypical hemolytic uremic syndrome in first trimester pregnancy successfully treated with eculizumab. Experimental hematology and oncology. 2017; 6: 4. https://doi.org/10.1186/s40164-017-0064-7
49. Fesenmeier M.F., Coppage K.H., Lambera D.S., et al. Acute fatty liver of pregnancy in 3 tertiary care centers. Am J Obstet Gynecol. 2005; 192(5): 1416-9. DOI: 10.1016/j.ajog.2004.12.035
50. Mauermann E., Vokt C., Tsakiris D.A., Tobler D., Girard T. Heparin-induced thrombocytopenia in pregnancy: an interdisciplinary challenge – a case report and literature review. International Journal of Obstetric Anesthesia. 2016; 26: 79-82. DOI: 10.1016/j.ijoa.2015.11.009
51. Greinacher A. Heparin-induced thrombocytopenia. N Engl J Med. 2015; 373(19):1883-4. doi: 10.1056/NEJMc1510993
52. Warkentin T.E., Heddle N.M. Laboratory diagnosis of immune heparin-induced thrombocytopenia. Curr Hematol Rep. 2003; 2(2):148-57.
53. Cuker A., Arepally G., Crowther M.A., et al. The HIT Expert Probability (HEP) Score: a novel pre-test probability model for heparin-induced thrombocytopenia based on broad expert opinion. J Thromb Haemost. 2010; 8(12): 2642-50.doi: 10.1111/j.1538-7836.2010.04059.x.
54. Joseph L., Gomes MP., Al Solaiman F., et al. External validation of the HIT Expert Probability (HEP) score. Thromb Haemost. 2015;113(3): 633-40. DOI: 10.1160/TH14-05-0472
55. Warkentin T.E., Aird W.C., Rand J.H. Platelet-endothelial interactions: sepsis, HIT, and antiphospholipid syndrome. Hematology Am Soc Hematol Educ Program. 2003: 497-519. PMID: 14633796
56. Fausett M.B., Vogtlander M., Beyer-Westendorf J., et al. Heparin-induced thrombocytopenia is rare in pregnancy. Am J Obstet Gynecol. 2001; 185(1):148-52. http://dx.doi.org/10.1067/mob.2001.114690
57. Elsaigh E., Thachil J., Nash M.J., et al. The use of fondaparinux in pregnancy. Br J Haematol. 2015;168(5):762-4. http://dx.doi.org/10.1111/bjh.1314
58. Li Z., Nardi M.A., Karpatkin S. Role of molecular mimicry to HIV-1 peptides in HIV-1-related immunologic thrombocytopenia. Blood. 2005;106(2): 572-576. DOI: 10.1182/blood-2005-01-0243
59. Zhang W., Nardi M.A., Borkowsky W., Li Z., Karpatkin S. Role of molecular mimicry of hepatitis С virus protein with platelet GPIIIa in hepatitis C-related immunologic thrombocytopenia. Blood. 2009;113(17): 4086-93. doi: 10.1182/blood-2008-09-181073
60. Khamashta M.A., Harris E.N., Gharavi A.E., Derue G., Gil A., Vázquez J.J., Hughes G.R. Immune mediated mechanism for thrombosis: antiphospholipid antibody binding to platelet membranes. Ann Rheum Dis. 1988; 47(10): 849-54. DOI: 10.1136/ard.47.10.849
61. Vazquez-Mellado J., Liorente L., Richaud-Patin Y., Alarcon-Segovia D. Exposure of anionic phospholipids upon platelet activation permits binding b2-glycoprotein-I and through it IgG antiphospholipid antibodies. Studies in platelets from patients with antiphospholipid syndrome and normal subjects. J Autoimmun. 1994; 7(3): 335-48.
62. Godeau B., Piette J.C., Fromont P., Intrator L., Schaeffer A., Bierling P. Specific antiplatelet glycoprotein autoantibodies are associated with the thrombocytopenia of primary antiphospholipid syndrome. Br J Haematol. 1997; 98(4): 873-9. DOI: 10.1046/j.1365-2141.1997.3063123.x
63. Gernsheimer T., McCrae K.R. Immune thrombocytopenic purpura in pregnancy. Curr Opin Hematol. 2007; 14(5): 574-80. DOI:10.1097/MOH.0b013e3282bf6dc2

Поступила 03.09.2019

Принята в печать 04.10.2019